- Home
- NABL vs PHVS Comparison
NABL vs PHVS Comparison
Compare NABL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NABL
- PHVS
- Stock Information
- Founded
- NABL 2000
- PHVS 2015
- Country
- NABL United States
- PHVS Switzerland
- Employees
- NABL N/A
- PHVS N/A
- Industry
- NABL Computer Software: Prepackaged Software
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- NABL Technology
- PHVS Health Care
- Exchange
- NABL Nasdaq
- PHVS Nasdaq
- Market Cap
- NABL 1.5B
- PHVS 1.3B
- IPO Year
- NABL N/A
- PHVS 2021
- Fundamental
- Price
- NABL $7.92
- PHVS $23.05
- Analyst Decision
- NABL Buy
- PHVS Buy
- Analyst Count
- NABL 4
- PHVS 6
- Target Price
- NABL $9.31
- PHVS $36.67
- AVG Volume (30 Days)
- NABL 721.9K
- PHVS 119.1K
- Earning Date
- NABL 08-07-2025
- PHVS 08-12-2025
- Dividend Yield
- NABL N/A
- PHVS N/A
- EPS Growth
- NABL N/A
- PHVS N/A
- EPS
- NABL 0.01
- PHVS N/A
- Revenue
- NABL $482,397,000.00
- PHVS N/A
- Revenue This Year
- NABL $9.54
- PHVS N/A
- Revenue Next Year
- NABL $8.71
- PHVS N/A
- P/E Ratio
- NABL $516.26
- PHVS N/A
- Revenue Growth
- NABL 7.40
- PHVS N/A
- 52 Week Low
- NABL $6.07
- PHVS $11.51
- 52 Week High
- NABL $13.12
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- NABL 51.12
- PHVS 55.97
- Support Level
- NABL $7.64
- PHVS $21.41
- Resistance Level
- NABL $8.12
- PHVS $24.52
- Average True Range (ATR)
- NABL 0.22
- PHVS 1.34
- MACD
- NABL 0.02
- PHVS -0.15
- Stochastic Oscillator
- NABL 71.92
- PHVS 47.24
About NABL N-able Inc.
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.